ResMed (RMD) Getting Somewhat Positive News Coverage, Accern Reports
Media coverage about ResMed (NYSE:RMD) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ResMed earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 45.8089565975714 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of ResMed (NYSE:RMD) traded up $0.07 on Monday, hitting $86.44. The company had a trading volume of 403,620 shares, compared to its average volume of 848,374. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. ResMed has a one year low of $60.13 and a one year high of $87.81. The company has a market capitalization of $12,260.00, a price-to-earnings ratio of 30.09, a P/E/G ratio of 1.92 and a beta of 0.78.
ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. The company had revenue of $523.66 million during the quarter, compared to analyst estimates of $506.08 million. ResMed had a return on equity of 21.53% and a net margin of 16.58%. ResMed’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 earnings per share. research analysts anticipate that ResMed will post 3 earnings per share for the current fiscal year.
RMD has been the subject of a number of research analyst reports. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a report on Friday, September 8th. Barclays lifted their target price on ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a report on Monday, September 25th. Zacks Investment Research raised ResMed from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Jefferies Group reaffirmed a “sell” rating and issued a $56.00 price objective on shares of ResMed in a report on Thursday, October 12th. Finally, Northland Securities reaffirmed a “sell” rating and issued a $55.00 price objective on shares of ResMed in a report on Friday, October 27th. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $67.57.
In related news, Director Peter C. Farrell sold 20,000 shares of ResMed stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $77.01, for a total transaction of $1,540,200.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction on Friday, December 1st. The shares were sold at an average price of $85.36, for a total value of $106,700.00. Following the transaction, the chief financial officer now owns 79,572 shares in the company, valued at $6,792,265.92. The disclosure for this sale can be found here. Insiders have sold 184,693 shares of company stock worth $15,149,955 over the last quarter. 1.77% of the stock is owned by company insiders.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.